Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 7,623 matching trials from the live ClinicalTrials.gov search.
Filters: Jacksonville, Florida Clear all
Terminated Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)

NCT02078960
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Omacetaxine mepesuccinate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Jacksonville, Florida • Atlanta, Georgia • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 30, 2026, 4:18 PM EDT
Completed Phase 3 Interventional Results available

The EVICEL® Neurosurgery Phase III Study

NCT02457546
View directory record Official record
Conditions
Cerebrospinal Fluid Leak
Interventions
EVICEL Fibrin Sealant, Hydrogel sealant
Biological · Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 30, 2026, 4:18 PM EDT
Completed Phase 2 Interventional Results available

Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease

NCT01696396
View directory record Official record
Conditions
Crohn's Disease
Interventions
Abrilumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
24
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 30, 2026, 4:18 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

NCT03504423
View directory record Official record
Conditions
Pancreatic Cancer Metastatic
Interventions
CPI 613, mFolfirinox, Folfirinox
Drug
Lead sponsor
Cornerstone Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
40
States / cities
Gilbert, Arizona • Tucson, Arizona • Duarte, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Oct 30, 2026, 4:18 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Accelerated Resolution Therapy for Early Maladaptive Grief

NCT05624879
View directory record Official record
Conditions
Grief
Interventions
Accelerated Resolution Therapy, Information and Support
Behavioral · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
55 Years and older
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
4
States / cities
Phoenix, Arizona • Clearwater, Florida • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 30, 2026, 4:18 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

NCT01644188
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo (for alirocumab), Ezetimibe, Placebo (for ezetimibe), Lipid Modifying Therapy (LMT)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Oct 30, 2026, 4:18 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy

NCT04164888
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
CIVI 007
Drug
Lead sponsor
Civi Biopharma, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
7
States / cities
Jacksonville, Florida • Port Orange, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 30, 2026, 4:18 PM EDT
Completed Phase 2 Interventional Results available

PF-06372865 In Subjects With Chronic Low Back Pain

NCT02262754
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
PF-06372865, Placebo, Naproxen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 30, 2026, 4:18 PM EDT
Completed Not applicable Interventional Results available

CONNECT Study - Clinical Evaluation Of Remote NotificatioN to rEduCe Time to Clinical Decision

NCT00402246
View directory record Official record
Conditions
Arrhythmia, Tachycardia, Atrial Fibrillation, Ventricular Fibrillation
Interventions
Remote Management, In-Office Care
Other
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
2,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
127
States / cities
Mobile, Alabama • Mesa, Arizona • Scottsdale, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2011 · Synced Oct 30, 2026, 4:18 PM EDT
No Longer Available No phase listed Expanded access

Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)

NCT04360486
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Anti-Sars-CoV-2 Convalescent Plasma
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
Not listed
U.S. locations
26
States / cities
Oceanside, California • San Diego, California • Fort Carson, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 30, 2026, 4:18 PM EDT
Completed Phase 3 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)

NCT03931941
View directory record Official record
Conditions
Clostridium Difficile Infection, Infection, Communicable Diseases
Interventions
RBX2660
Drug
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
46
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • Oxnard, California + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 30, 2026, 4:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types

NCT03085888
View directory record Official record
Conditions
Neoplasms, Cancer
Interventions
Not listed
Lead sponsor
GRAIL, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
99,481 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
35
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Elk Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Oct 30, 2026, 4:18 PM EDT
Active, not recruiting Phase 4 Interventional

REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

NCT06041386
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab, Spirometry
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
28
States / cities
La Jolla, California • Newport Beach, California • Aurora, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 30, 2026, 4:18 PM EDT
Completed Phase 3 Interventional Results available

An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT02925494
View directory record Official record
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
Estradiol/Norethindrone Acetate, Elagolix
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
121
States / cities
Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 30, 2026, 4:18 PM EDT
Active, not recruiting Phase 3 Interventional

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

NCT03793166
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Soft Tissue, Metastatic Malignant Neoplasm in the Viscera, Rhabdoid Tumor of the Kidney, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
858
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 554 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 4:18 PM EDT
Withdrawn Phase 3 Interventional

A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease

NCT02974322
View directory record Official record
Conditions
Crohn Disease
Interventions
GED-0301, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
136
States / cities
Litchfield Park, Arizona • Mesa, Arizona • Phoenix, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 30, 2026, 4:18 PM EDT
Completed Phase 4 Interventional Results available

PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment

NCT04634162
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Cangrelor, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 30, 2026, 4:18 PM EDT
Completed No phase listed Observational Results available

Post Approval Study of the remedē System

NCT03425188
View directory record Official record
Conditions
Central Sleep Apnea
Interventions
Not listed
Lead sponsor
Respicardia, Inc.
Industry
Eligibility
21 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Los Angeles, California • Jacksonville, Florida • Downers Grove, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Oct 30, 2026, 4:18 PM EDT
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

A Study of Renal Microvessel Imaging for Chronic Kidney Disease

NCT05764642
View directory record Official record
Conditions
Healthy, Chronic Kidney Diseases
Interventions
Definity, Super-resolution ultrasound imaging
Drug · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 30, 2026, 4:18 PM EDT
Terminated Not applicable Interventional

A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy

NCT01845454
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
trūFreeze™ Spray Cryotherapy
Device
Lead sponsor
CSA Medical, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
6
States / cities
Jacksonville, Florida • Baltimore, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2016 · Synced Oct 30, 2026, 4:18 PM EDT
Completed Not applicable Interventional Results available

Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation

NCT04702451
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Dispersion ablation + PVI, VX1, PVI
Procedure · Device
Lead sponsor
Volta Medical
Industry
Eligibility
18 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Jacksonville, Florida • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 30, 2026, 4:18 PM EDT
Completed Phase 2 Interventional

Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels

NCT00813527
View directory record Official record
Conditions
Hyperlipidemias
Interventions
Lapaquistat acetate and fenofibrate, Fenofibrate
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
32
States / cities
Huntsville, Alabama • Sierra Vista, Arizona • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Oct 30, 2026, 4:18 PM EDT
Completed Phase 3 Interventional Results available

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

NCT02621931
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
179
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 30, 2026, 4:18 PM EDT
Not listed Phase 3 Interventional Results available

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer

NCT00382070
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Placebo
Drug · Other
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
3,966 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2025
U.S. locations
777
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 523 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 30, 2026, 4:18 PM EDT